Skip to main content

Mineralys Therapeutics, Inc 10-Q for FY2026 Q3

Mineralys Therapeutics, Inc. (MLYS)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Mineralys Therapeutics, Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Mineralys Therapeutics said the FDA accepted its lorundrostat NDA for hypertension, with a PDUFA target date of December 22, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$57.33M
compared with a net loss of $36.93M a year earlier
Diluted EPS
-$0.64
compared with -$0.52 a year earlier